Based on data from key clinical trials evaluating the use of SGLT2 inhibitors, GLP‐1 RAs, and the nonsteroidal MRA finerenone in addition to background RAS therapy in participants with CKD and diabetes, a pillared approach to therapy has been suggested, which is similar to the pillared approach that is currently in use within the treatment landscape for HF [57, 58]. The gene discussed is SLC5A2; the disease is hydrops fetalis.